Skip to main content
. Author manuscript; available in PMC: 2023 May 22.
Published in final edited form as: FASEB J. 2021 May;35(5):e21467. doi: 10.1096/fj.202002387R

Figure 1.

Figure 1.

Diabetic kidney disease (DKD) phenotype for the 8 experimental groups to demonstrate both the separate and combined effects of diabetes status (db/db) and eNOS deletion. Urine volume (panel A), albuminuria (panel B), and mesangial expansion as quantified by mesangial index (panel C) increased by diabetes alone, but not by eNOS deletion alone. Albuminuria, mesangial index, and the percentage of totally sclerosed glomeruli increased in db/db eNOS−/− compared to db/db eNOS+/+ animals (panels B-D). There were only occasional sclerosed glomeruli in the nondiabetic groups (up to a maximum of 2.2% in the eNOS−/− nondiabetic mice; not shown) so these were not included in the analysis. RAS inhibitor treatment significantly ameliorated both albuminuria and mesangial expansion in the db/db eNOS−/− animals. *p < 0.05, ***p < 0.001. T, indicates RAS inhibitor treatment.